Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04264260 | Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | completed | Phase 2 | 42 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Sep 8, 2025 |
| clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07156058 | MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer | recruiting | N/A | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06202131 | Use of Ctdna in Patients With Gastrointestinal Tract Tumors(ctdna-GI) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07149558 | Volume-Restricted Resection for Perihilar Cholangiocarcinoma | not yet recruiting | — | 300 | Yongjun ChenOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT05044065 | Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex)(PREV-Ex) | completed | N/A | 52 | Karolinska InstitutetOTHER | 2 | Aug 27, 2025 | clinicaltrials |
| NCT04871321 | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | completed | — | 119 | CHA UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05942807 | Observational Monocentric Study on Biliary Tract Cancer (BABEL)(BABEL) | recruiting | — | 560 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06728358 | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract(SOCRATE) | active not recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07135544 | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | recruiting | Phase 2 | 37 | Yongjun ChenOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT07129018 | Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer | not yet recruiting | Phase 2 | 63 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma(PEHRICCA) | not yet recruiting | Phase 2 | 49 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03579771 | Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT07070700 | Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-02) | recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05678218 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma(POELH-II) | completed | — | 245 | Erasmus Medical CenterOTHER | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05265208 | Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer(SIROCHO) | recruiting | Phase 2 | 62 | Center Eugene MarquisOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07105852 | Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma | recruiting | Phase 2 | 59 | Sir Run Run Shaw HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06541652 | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers(FFCD-2205) | recruiting | — | 150 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02375880 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | completed | Phase 1 | 51 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101237 | An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer. | recruiting | — | 308 | Peking Union Medical College HospitalOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04993131 | Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma(TESLA II) | recruiting | N/A | 15 | Oslo University HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | terminated | — | 19 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092397 | Artificial Intelligence-based Tumor Microenvironment Analysis for Prognosis Prediction in Gallbladder Cancer | completed | — | 266 | Samsung Medical CenterOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT03377179 | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma | completed | Phase 2 | 65 | RedHill Biopharma LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03704480 | Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.(IMMUNO-BIL) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04935853 | Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study | recruiting | — | 1,350 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04172402 | NGS as the First-line Treatment in Advanced Biliary Tract Cancer | completed | Phase 2 | 48 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | terminated | — | 1 | Seoul National University HospitalOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06493734 | Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma(STRONG II) | recruiting | N/A | 30 | Erasmus Medical CenterOTHER | 2 | Jul 15, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | terminated | — | 14 | University of WashingtonOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06964425 | Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study | recruiting | N/A | 20 | University Hospital OlomoucOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06978114 | A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer | recruiting | Phase 2 | 46 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma | withdrawn | Early Phase 1 | 0 | Shanghai Changzheng HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials